Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNFT GENFIT	$3.79 +1.6%	$3.90	$2.55 ▼ $6.42	$186.51M	1.14	3,829 shs	670 shs
NUVB Nuvation Bio	$2.32 +3.6%	$2.20	$1.54 ▼ $3.45	$762.19M	1.35	4.20 million shs	4.26 million shs
PHAR Pharming Group	$11.30 -6.6%	$10.89	$6.73 ▼ $17.08	$829.03M	0.02	10,181 shs	14,628 shs
QURE uniQure	$14.30 +1.3%	$14.67	$4.45 ▼ $19.18	$774.72M	0.11	1.32 million shs	879,172 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNFT GENFIT	-0.53%	-1.58%	+2.19%	-11.40%	-5.09%
NUVB Nuvation Bio	-2.83%	-3.25%	+1.59%	+2.05%	-21.02%
PHAR Pharming Group	-8.54%	-1.22%	+20.40%	+21.00%	+51.25%
QURE uniQure	+6.11%	+2.33%	-2.15%	+10.00%	+97.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNFT GENFIT	1.2891 of 5 stars	3.5	3.0	0.0	0.0	0.0
NUVB Nuvation Bio	2.0173 of 5 stars	3.6	0.0	2.4	3.3	0.0
PHAR Pharming Group	2.6503 of 5 stars	3.5	5.0	1.8	0.0	0.6
QURE uniQure	2.075 of 5 stars	3.5	2.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNFT GENFIT	3.00	Buy	$13.00	243.01% Upside
NUVB Nuvation Bio	3.17	Buy	$7.33	216.09% Upside
PHAR Pharming Group	3.00	Buy	$30.00	165.49% Upside
QURE uniQure	2.91	Moderate Buy	$36.55	155.56% Upside

Current Analyst Ratings Breakdown

Latest GNFT, NUVB, QURE, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
7/30/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$47.00
7/29/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
5/19/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNFT GENFIT	$76.77M	2.47	$0.07 per share	53.33	$1.50 per share	2.53
NUVB Nuvation Bio	$7.87M	100.31	N/A	N/A	$1.10 per share	2.11
PHAR Pharming Group	$297.20M	2.60	$0.07 per share	163.23	$3.50 per share	3.23
QURE uniQure	$27.12M	28.93	N/A	N/A	($0.07) per share	-204.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	N/A
PHAR Pharming Group	-$11.84M	-$0.13	N/A	376.67	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)
QURE uniQure	-$239.56M	-$3.92	N/A	N/A	N/A	-1,387.98%	-1,010.74%	-33.27%	N/A

Latest GNFT, NUVB, QURE, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million
7/29/2025	Q2 2025	QURE uniQure	-$0.89	-$0.69	+$0.20	-$0.69	$5.00 million	$5.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNFT GENFIT	0.08	1.23	1.23
NUVB Nuvation Bio	0.13	9.39	9.38
PHAR Pharming Group	0.38	2.79	2.07
QURE uniQure	1.53	9.98	9.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNFT GENFIT	2.24%
NUVB Nuvation Bio	61.67%
PHAR Pharming Group	0.03%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
GNFT GENFIT	4.20%
NUVB Nuvation Bio	29.93%
PHAR Pharming Group	2.07%
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable
QURE uniQure	500	54.87 million	52.24 million	Optionable

GNFT, NUVB, QURE, and PHAR Headlines

Recent News About These Companies

uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen

August 4, 2025 | americanbankingnews.com

Cantor Fitzgerald Predicts Weaker Earnings for uniQure

August 3, 2025 | americanbankingnews.com

Leerink Partnrs Has Bullish Estimate for uniQure Q3 Earnings

August 3, 2025 | americanbankingnews.com

William Blair Has Positive Outlook for uniQure Q3 Earnings

August 3, 2025 | americanbankingnews.com

What is HC Wainwright's Forecast for uniQure Q3 Earnings?

August 2, 2025 | americanbankingnews.com

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

July 31, 2025 | zacks.com

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

July 29, 2025 | seekingalpha.com

uniQure Narrows Loss in Fiscal Q2

July 29, 2025 | fool.com

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

July 29, 2025 | zacks.com

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

July 29, 2025 | globenewswire.com

uniQure to Announce Second Quarter 2025 Financial Results

July 22, 2025 | globenewswire.com

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, NUVB, QURE, and PHAR Company Descriptions

GENFIT NASDAQ:GNFT

$3.79 +0.06 (+1.61%)

As of 03:59 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Nuvation Bio NYSE:NUVB

$2.32 +0.08 (+3.57%)

Closing price 03:59 PM Eastern

Extended Trading

$2.35 +0.03 (+1.08%)

As of 07:58 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Pharming Group NASDAQ:PHAR

$11.30 -0.80 (-6.61%)

Closing price 04:00 PM Eastern

Extended Trading

$11.33 +0.03 (+0.27%)

As of 04:10 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

uniQure NASDAQ:QURE

$14.30 +0.18 (+1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$14.32 +0.02 (+0.14%)

As of 07:52 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time